ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Early in vitro and in vivo studies showed a marked ability of imatinib to kill CML cells by competitively binding to the ATP binding site of the ABL kinase domain, which paved the way for a dramatic change in the management and prognosis of CML (Druker et al., 2001).